Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 13 sources cited
Key Takeaways
- Most patients feel reduced appetite within the first two weeks at the starting 0.25 mg dose, but measurable weight loss usually begins between weeks 4 and 8.
- The 1.0 mg dose (week 9 to 12) is when most patients first see consistent weekly weight loss of 1 to 2 lb per week.
- The full FDA-approved maintenance dose of 2.4 mg, reached at week 17, drives the bulk of total weight loss in the STEP 1 trial.
- In the STEP 1 trial, average weight loss was 6.0% by week 12 and 14.9% by week 68 (Wilding et al., NEJM 2021).
- "Starts working" depends on what you measure: appetite at week 1, scale weight at week 4, and clinically meaningful loss at week 16+.
Direct answer (40-60 words)
Wegovy starts suppressing appetite at the starting 0.25 mg dose within 1 to 2 weeks. Measurable weight loss typically begins at the 0.5 mg dose (weeks 5 to 8). Most patients see consistent 1 to 2 lb weekly losses once they reach 1.0 mg at weeks 9 to 12, with peak weight loss at the 2.4 mg maintenance dose.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- The standard Wegovy titration schedule
- What "working" means at each dose
- Week-by-week appetite and weight changes
- The STEP 1 trial data, by dose
- Why the starting dose feels like nothing
- When to expect appetite suppression vs scale loss
- What if Wegovy isn't working at my current dose
- Compounded semaglutide and the same dose curve
- FAQ
- Footer disclaimers
The standard Wegovy titration schedule
Wegovy (semaglutide 2.4 mg) uses a 16-week titration before patients reach the full maintenance dose. The schedule, from the FDA label:
| Phase | Weeks | Dose | Purpose |
|---|---|---|---|
| Initiation | 1-4 | 0.25 mg weekly | Tolerate the medication, minimize nausea |
| Titration 1 | 5-8 | 0.5 mg weekly | Begin appetite suppression |
| Titration 2 | 9-12 | 1.0 mg weekly | Consistent appetite control |
| Titration 3 | 13-16 | 1.7 mg weekly | Late-stage titration |
| Maintenance | 17+ | 2.4 mg weekly | Full FDA-approved maintenance dose |
The titration schedule exists because semaglutide's most common side effects (nausea, vomiting, diarrhea, constipation) are dose-dependent. Starting at 2.4 mg directly would cause severe GI symptoms in most patients. Stepping up by doubling the dose every four weeks lets the gut adapt before the next increase.
Most patients reach 2.4 mg at week 17. Some patients hold at lower doses (1.0 or 1.7 mg) if side effects are intolerable at the higher doses or if they're losing weight at a steady clip without needing to escalate.
What "working" means at each dose
The phrase "Wegovy is working" can mean three different things, each starting at a different dose:
Appetite suppression. Most patients notice reduced hunger and earlier fullness within 7 to 14 days of the first 0.25 mg injection. The mechanism (slowed gastric emptying plus central appetite signaling, per Drucker, Cell Metabolism 2024) doesn't require a high dose to activate. The intensity of the effect grows with dose, but the on-off switch flips at the starting dose for most people.
Measurable weight loss. The scale starts to move once appetite suppression translates into a sustained calorie deficit. For most patients that's weeks 4 to 8, when the dose has increased from 0.25 mg to 0.5 mg. STEP 1 trial data shows average weight loss of 1.6% by week 4 and 4.0% by week 8.
Clinically meaningful weight loss. A 5% loss is the FDA's threshold for "clinically meaningful" because that level of loss produces measurable improvements in blood pressure, lipids, and HbA1c. Most patients hit 5% between weeks 12 and 16, on the 1.0 to 1.7 mg dose. The full 14.9% average loss in STEP 1 came at the 2.4 mg dose held for an additional 52 weeks.
So "at what dose does Wegovy start working" depends on which milestone you're asking about.
Week-by-week appetite and weight changes
The patterns reported by patients in clinical trials and post-market surveillance, by week:
| Week | Dose | What patients notice |
|---|---|---|
| 1 | 0.25 mg | Mild nausea on injection day. Smaller appetite at lunch and dinner within 3-5 days. |
| 2 | 0.25 mg | Earlier fullness. Sometimes 1-2 lb of water-weight loss. Stool changes (constipation more common than diarrhea). |
| 3 | 0.25 mg | Adapted GI tolerance. Appetite suppression more pronounced, especially for processed and high-fat foods. |
| 4 | 0.25 mg | First scale reduction usually visible: 2-4 lb loss for most patients. |
| 5-6 | 0.5 mg | Increase in nausea on dose-change day. Stronger appetite suppression by mid-week. |
| 7-8 | 0.5 mg | First sustained 1-2 lb/week loss for most patients. Total loss now 4-7 lb. |
| 9-10 | 1.0 mg | Marked food aversion to fatty or rich meals. Some patients report loss of pleasure in eating. |
| 11-12 | 1.0 mg | Average total loss in STEP 1 was 6.0%. For a 220 lb starting weight, that's 13.2 lb. |
| 13-14 | 1.7 mg | Weight loss continues at 1-2 lb/week if calorie intake remains controlled. |
| 15-16 | 1.7 mg | End of titration. Maintenance dose reached at week 17. |
| 17-24 | 2.4 mg | Loss continues, often plateauing temporarily around week 20. |
| 25-52 | 2.4 mg | Slower but persistent loss. STEP 1 mean loss at week 52: 12.4%. |
| 53-68 | 2.4 mg | Final 1-2% of total loss achieved. STEP 1 final mean loss: 14.9%. |
Image suggestion: line chart with x-axis as weeks (1 to 68) and y-axis as cumulative weight loss percentage, with horizontal bands showing each dose phase color-coded.
These are averages from a clinical trial population. Individual response varies widely. STEP 1 reported that 86.4% of treated patients achieved at least 5% weight loss at week 68, and 32.0% achieved at least 20% loss.
The STEP 1 trial data, by dose
The STEP 1 trial (Wilding et al., NEJM 2021) is the primary regulatory data set for Wegovy at the 2.4 mg maintenance dose. The trial enrolled 1,961 adults with overweight or obesity and randomized them to semaglutide 2.4 mg or placebo over 68 weeks.
| Time point | Dose | Mean weight loss (semaglutide) | Mean weight loss (placebo) |
|---|---|---|---|
| Week 12 | 1.0 mg | -6.0% | -1.4% |
| Week 20 | 2.4 mg (3 weeks at maintenance) | -10.3% | -2.0% |
| Week 28 | 2.4 mg | -12.5% | -2.4% |
| Week 40 | 2.4 mg | -14.0% | -2.6% |
| Week 52 | 2.4 mg | -14.9% | -2.6% |
| Week 68 | 2.4 mg | -14.9% | -2.4% |
The dose-response curve is meaningful: roughly half of total weight loss happens during the 16-week titration, and the other half happens in the first 16 weeks at the 2.4 mg maintenance dose. After week 32 or so, weight loss plateaus for most patients on a fixed dose.
For comparison, the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023) at 2.4 mg semaglutide showed weight loss of 9.4% at week 104, in patients without obesity diagnosis. The lower number reflects that patients on average had less excess weight to lose.
Why the starting dose feels like nothing
Patients often write to providers around week 2 or 3 saying "I don't feel any different" or "this doesn't work." There are real biological reasons the 0.25 mg dose feels subtle:
It's intentionally subtherapeutic for weight loss. The 0.25 mg dose is meant to acclimate the gut, not to drive weight loss. The pharmacokinetic models (Granhall et al., Clinical Pharmacokinetics 2019) predict negligible appetite suppression at 0.25 mg compared with 1.0 to 2.4 mg.
Steady-state takes 4 to 5 weeks. Semaglutide has a half-life of about 7 days. After a single 0.25 mg dose, blood levels build over 4 to 5 weeks before reaching steady-state. Even at the same dose, week 4 produces stronger appetite suppression than week 1.
Habit drives much of early eating behavior. Mealtime cues (3 PM snack, after-dinner couch eating, weekend brunch) are strong even when physical hunger is muted. Patients who notice "I'm not as hungry but I still ate normally" are reporting an honest disconnect between hunger signal and habit-driven eating.
The clinical advice for patients in week 1 to 3 is: don't change anything yet. Don't restrict aggressively, don't change exercise dramatically. Use the time to track meals and identify habit-driven eating moments. The dose escalation at week 5 will create the conditions for behavior change to take hold.
When to expect appetite suppression vs scale loss
These two outcomes don't track each other. Some patients report strong appetite suppression starting week 1 but no scale loss until week 6. Others see modest appetite changes and immediate scale loss. The pattern depends on baseline eating behavior:
- Patients whose excess intake came from snacking and grazing tend to see early scale loss. Reduced hunger between meals translates directly into a calorie deficit.
- Patients whose excess intake came from large structured meals see appetite suppression at the meal level, which can take a few weeks to translate to scale loss because portion habits take time to retrain.
- Patients with metabolic adaptation from prior dieting sometimes see slow scale loss despite strong appetite suppression. The body's energy expenditure has down-regulated and takes 8 to 12 weeks to recalibrate.
A simple framework: at week 4, if you've lost any weight at all (even 1 lb) on the 0.25 mg dose, the medication is working. If you've lost nothing, the appetite suppression hasn't yet translated into a calorie deficit, but the dose escalation at week 5 usually closes the gap.
What if Wegovy isn't working at my current dose
A small percentage of patients (roughly 13.6% in STEP 1) don't reach 5% weight loss even at the maintenance dose. The clinical evaluation if you're not responding by week 16 typically covers:
Verify adherence. Missed weekly doses or improper storage that degrades the peptide can blunt response. The pen should be refrigerated until use; once in use, it's stable at room temperature for 28 days.
Verify calorie intake. GLP-1 medications work by reducing hunger, but they don't override conscious overeating. A patient who continues to consume 3,000+ calories per day from energy-dense foods can still gain weight on the maintenance dose. Food tracking for two weeks is the standard diagnostic.
Consider tirzepatide. SURMOUNT-2 and SURPASS-2 (Frias et al., NEJM 2021; Garvey et al., Lancet 2023) showed tirzepatide produces 18 to 22% weight loss versus semaglutide's 14.9%. Patients who stall on Wegovy sometimes respond to a switch.
Evaluate underlying conditions. Hypothyroidism, PCOS, sleep apnea, and certain medications (steroids, antipsychotics, some antidepressants) can blunt response. Lab work and a medication review are reasonable.
Behavioral support. Many patients benefit from concurrent dietary counseling and resistance training during the maintenance phase, particularly to preserve lean mass.
If you've followed the titration, taken every dose, controlled calorie intake, and still aren't responding by week 16, the conversation with your provider should cover a medication switch or additional support, not just "wait longer."
Compounded semaglutide and the same dose curve
Compounded semaglutide is dispensed by state-licensed compounding pharmacies in response to individual prescriptions. The active ingredient is the same molecule used in branded Wegovy and Ozempic, but compounded versions are not FDA-approved and are not interchangeable with the branded products.
Most compounded semaglutide protocols follow the same titration schedule used for Wegovy, with doses converted from milligrams into units on a U-100 insulin syringe. (See our unit conversion guide for the math.)
Patients on compounded semaglutide generally report a similar response curve: appetite suppression in week 1 to 2, first scale loss between week 4 and 8, consistent loss from week 9 onward. The clinical trial data on compounded versions is sparse because compounded products aren't required to undergo FDA trials, so most "compounded works at the same dose" claims rely on branded data plus pharmacokinetic equivalence assumptions.
For more on the differences between compounded and branded semaglutide, see our overview at compounded vs branded semaglutide.
FAQ
At what dose does Wegovy start working? Appetite suppression starts at the 0.25 mg starting dose within 1 to 2 weeks. Measurable weight loss typically begins at the 0.5 mg dose during weeks 5 to 8. Consistent 1 to 2 lb per week loss usually starts at the 1.0 mg dose during weeks 9 to 12.
How long does it take to feel Wegovy working? Most patients notice reduced appetite within 7 to 14 days of the first injection. Side effects like nausea or constipation often appear in the same window. Scale weight changes typically follow 2 to 3 weeks later.
What week of Wegovy do you start losing weight? Most patients see their first measurable weight loss between weeks 4 and 6, while still on the 0.25 mg or early 0.5 mg dose. The STEP 1 trial reported an average 1.6% weight loss at week 4.
How much weight will I lose in the first month on Wegovy? Most patients lose 2 to 6 lb in the first month on the 0.25 mg dose. The STEP 1 trial average at week 4 was about 4 lb for a typical 230 lb starting weight. Individual response varies based on baseline eating habits, calorie intake, and adherence.
Why isn't Wegovy working at the starting dose? The 0.25 mg dose is intentionally subtherapeutic. It's meant to let the gut adapt to the medication before the dose escalates at week 5. Patients who notice no change in week 1 or 2 are responding normally. Most see effects by week 4.
Does Wegovy work better at higher doses? Yes, with diminishing returns. The dose-response curve from STEP 1 shows progressive weight loss as the dose increases from 0.25 to 2.4 mg. About half of total weight loss occurs during the 16-week titration, and the other half occurs in the first 16 weeks at maintenance.
What's the maintenance dose of Wegovy? The FDA-approved maintenance dose for Wegovy is 2.4 mg weekly, reached at week 17 of the titration. Some patients hold at lower doses (1.0 or 1.7 mg) if they're losing weight steadily or experiencing intolerable side effects at higher doses.
Can I lose weight on the 0.25 mg or 0.5 mg dose alone? Yes, but loss is typically modest. STEP 1 data shows about 4% weight loss by the end of the 0.5 mg dose period (week 8). Some patients respond strongly to lower doses and choose to hold rather than escalate, which can be appropriate with provider guidance.
Is Wegovy still working if I've stopped losing weight? Plateaus are normal during maintenance. Most patients reach a weight-loss plateau between week 32 and 52, where loss slows or stops. Wegovy continues to work in that it prevents weight regain. If the plateau happens before week 32, calorie intake review is the first step.
What if I miss a dose during titration? A missed dose within 5 days of the scheduled day can be taken as soon as remembered. If more than 5 days have passed, skip the missed dose and resume at the next scheduled time. Don't double the dose to make up. The titration schedule may need to restart if more than 2 weeks have lapsed.
How long do I need to stay on Wegovy? Wegovy is intended for long-term use. The STEP 4 trial (Rubino et al., JAMA 2021) showed that patients who stopped Wegovy at week 20 regained roughly two-thirds of lost weight by week 68. Continued use maintains the loss.
Is compounded semaglutide as effective as Wegovy? Compounded semaglutide uses the same active ingredient but is not FDA-approved and hasn't been studied in dedicated clinical trials at the same scale as branded Wegovy. Patients on compounded semaglutide generally report a similar response curve, though direct head-to-head trial comparisons don't exist.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. 2021;397(10278):971-984.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325(14):1403-1413.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325(14):1414-1425.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023;389:2221-2232.
- Drucker DJ. The cellular and molecular biology of GLP-1 receptor signaling. Cell Metabolism. 2024;36(2):258-276.
- Granhall C, Donsmark M, Blicher TM, et al. Safety, tolerability, and pharmacokinetics of single-dose oral semaglutide. Clinical Pharmacokinetics. 2019;58(6):781-791.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021;385:503-515.
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). The Lancet. 2023;402(10402):613-626.
- U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. 2024.
- Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine. 2022;70(1):5-13.
- American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016;375:1834-1844.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →